These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 8011008

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The pharmacokinetics and pharmacodynamics of the oral iron chelator deferiprone (L1) in relation to hemoglobin levels.
    Fassos FF, Klein J, Fernandes D, Matsui D, Olivieri NF, Koren G.
    Int J Clin Pharmacol Ther; 1996 Jul; 34(7):288-92. PubMed ID: 8832304
    [Abstract] [Full Text] [Related]

  • 3. New concepts of iron and aluminium chelation therapy with oral L1 (deferiprone) and other chelators. A review.
    Kontoghiorghes GJ.
    Analyst; 1995 Mar; 120(3):845-51. PubMed ID: 7741239
    [Abstract] [Full Text] [Related]

  • 4. Chelation of aluminium by combining DFO and L1 in rats.
    Blanusa M, Prester L, Varnai VM, Pavlović D, Kostial K, Jones MM, Singh PK.
    Toxicology; 2000 Jul 05; 147(3):151-6. PubMed ID: 10924797
    [Abstract] [Full Text] [Related]

  • 5. Competition between deferiprone, desferrioxamine and other chelators for iron and the effect of other metals.
    Sheppard LN, Kontoghiorghes GJ.
    Arzneimittelforschung; 1993 Jun 05; 43(6):659-63. PubMed ID: 8352819
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Elimination of aluminum via continuous ambulatory peritoneal dialysis].
    Passlick J, Wilhelm M, Busch T, Grabensee B, Ohnesorge FK.
    Dtsch Med Wochenschr; 1989 Jan 06; 114(1):9-13. PubMed ID: 2910699
    [Abstract] [Full Text] [Related]

  • 11. Oral iron chelation therapy with deferiprone. Monitoring of biochemical, drug and iron excretion changes.
    Kontoghiorghes GJ, Bartlett AN, Sheppard L, Barr J, Nortey P.
    Arzneimittelforschung; 1995 Jan 06; 45(1):65-9. PubMed ID: 7893273
    [Abstract] [Full Text] [Related]

  • 12. Correction of haemodialysis-associated anaemia by deferoxamine. Effects on serum aluminum and iron overload.
    von Bonsdorff M, Sipilä R, Pitkänen E.
    Scand J Urol Nephrol Suppl; 1990 Jan 06; 131():49-54. PubMed ID: 2075470
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity.
    McCarthy JT, Milliner DS, Johnson WJ.
    Q J Med; 1990 Mar 06; 74(275):257-76. PubMed ID: 2117295
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Continuous ambulatory peritoneal dialysis: three years' experience.
    Ramos JM, Gokal R, Siamopolous K, Ward MK, Wilkinson R, Kerr DN.
    Q J Med; 1983 Mar 06; 52(206):165-86. PubMed ID: 6611839
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Urinary iron excretion depends on the mode of administration of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with homozygous beta-thalassemia.
    Fassos FF, Klein J, Fernandes D, Matsui D, Olivieri NF, Koren G.
    Clin Pharmacol Ther; 1994 Jan 06; 55(1):70-5. PubMed ID: 8299320
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.